Puliafito, B., Lei, M., Yee, A., Cirstea, D., Branagan, A., Agyemang, E., Harrington, C., Sanclemente, K., Packer, L., Wright, A., Kim, E. B., McCormick, B., Mosaheb, K., Lin, J., Horick, N., Hua, E., Nadeem, O., Frigault, M., Rosenblatt, J., Raje, N. (2025). Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-5824